Sensient Technologies
SXT
113.85
-2.58
-2.22%
Sensient Technologies
US · SXT
#2027 by market cap
Listed 1970
113.85
-2.58
-2.22%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Rating change
UBS Maintains Sensient Technologies(SXT.US) With Buy Rating, Maintains Target Price $143Market Newswire · 2026/7/6
-
UBS Maintains Sensient Technologies(SXT.US) With Buy Rating, Raises Target Price to $157Market Newswire · 2026/9/30
-
Rating change
Baird Maintains Sensient Technologies(SXT.US) With Buy Rating, Raises Target Price to $125Market Newswire · 2025/7/4
-
Company notice
China SXT Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-Streeterville Capital LLC(9.99*%),Streeterville Management LLC(9.99*%), etc.SEC · 2023/3/30
-
China SXT Pharmaceuticals Inc. Announces $12 Million Registered Direct OfferingPR Newswire · 2026/10/8
-
Company notice
China SXT Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-Streeterville Capital LLC(9.99*%),Streeterville Management LLC(9.99*%), etc.SEC · 2022/8/26
-
Rating change
Baird Maintains Sensient Technologies(SXT.US) With Buy Rating, Announces Target Price $140Market Newswire · 2026/7/27
-
China SXT Pharmaceuticals Announces 1-For-100 Reverse Stock Split, Effective Oct. 26Benzinga · 2026/10/22
-
Company notice
China SXT Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Streeterville Capital LLC(0%),Streeterville Management LLC(0%), etc.SEC · 2023/3/30
-
Rating change
Rothschild & Co Redburn Initiates Sensient Technologies(SXT.US) With Hold Rating, Announces Target Price $125Market Newswire · 2026/7/8
-
Company notice
China SXT Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Streeterville Capital LLC(9.99%),Streeterville Management LLC(9.99%), etc.SEC · 2024/10/26
-
Rating change
Baird Maintains Sensient Technologies(SXT.US) With Buy Rating, Raises Target Price to $93Market Newswire · 2025/4/29
-
UBS Maintains Sensient Technologies(SXT.US) With Buy Rating, Maintains Target Price $154Market Newswire · 2026/11/2
-
GUIDANCE: (SXT) Sensient Technologies Expects 2026 EPS Range $4.15 - $4.20, Vs. FactSet Est of $4.20MT Newswires · 2026/10/30
-
Company notice
China SXT Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-Lind Global Fund II LP(9.9%),Lind Global Fund II LLC(9.9%), etc.SEC · 2022/1/22
-
Rating change
Baird Maintains Sensient Technologies(SXT.US) With Buy Rating, Maintains Target Price $85Market Newswire · 2024/10/28
-
Rating change
Baird Maintains Sensient Technologies(SXT.US) With Buy Rating, Raises Target Price to $85Market Newswire · 2024/7/29
-
Rating change
UBS Maintains Sensient Technologies(SXT.US) With Buy Rating, Raises Target Price to $155Market Newswire · 2026/7/27
-
Rating change
UBS Initiates Sensient Technologies(SXT.US) With Buy Rating, Announces Target Price $115Market Newswire · 2026/4/1
-
Rating change
UBS Maintains Sensient Technologies(SXT.US) With Buy Rating, Raises Target Price to $143Market Newswire · 2026/4/28
-
Rating change
Baird: Maintaining the Sensient Technologies (SXT.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $70.00 to $80.00.Zhitong Finance · 2024/4/29
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Sensient Technologies discussion 0 comments